AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75N93023C00012PLURI BIOTECH LTD
Overview
Award facts
- Net obligations
- $2.86M
- $2,861,615of $4.18M potential value
- Outlays (paid to date)
- $2.33M
- $2.33M paid of $2.86M obligated$2,325,394
- Period of performance
- Jul 1, 2023 to Apr 15, 2025
- Ended
- Modifications
- 3
- Latest action Apr 15, 2025
- Contract type
- Definitive contract
- PIID 75N93023C00012
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
DEVELOPMENT OF PLX-R18 CELL THERAPY AS A COUNTERMEASURE FOR HEMATOPOIETIC ACUTE RADIATION SYNDROME
Dates and value
- Award date
- Signed on Jun 30, 2023
- Potential end of performance
- Apr 14, 2025
- Current value
- $2,861,615Base and exercised options
- Potential value (if all options are exercised)
- $4,175,467
Obligations by fiscal year of action
- FY2024: $1,416,470
- FY2023: $1,445,145
Total across 2 fiscal years: $2,861,615
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Apr 15, 2025. View on USAspending · Recipient on SAM.gov
Recipient
LocationHAIFA, ISR
UEIMEDCUE4LMZE6
CAGE code3704A
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeInternational org
Parent companyPLURISTEM THERAPEUTICS INC
Business types and certifications
For-profit organizationInternational organizationLimited liability company
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIAID
- Funded from
- Nih office of the director (0846)Program activities075-0846Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Israel
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost no feeS
- Offers received
- 16
Solicitation and notices
- Solicitation ID
- 75N93021R00019
- Solicitation date
- Dec 17, 2021
- Notices
- Solicitation posted Jan 28, 2022
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- Development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- Yes
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Jun 30, 2023Base obligation at award: $1,445,145
- Latest action
- Apr 15, 2025 — Terminated for convenienceModification P00003
- Latest substantive action
- Apr 15, 2025 — Terminated for convenienceModification P00003
- Actions by type
- Base award1
- Terminated for convenience1
- Option exercised1
- Other administrative action1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- No
- Simplified procedures for commercial items
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- Foreign-owned business incorporated in the U.S.C
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N930
- Transactions recorded under this award key
- 4
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N930
- Treasury accounts
- 075-2023/2023-0846-000
- 075-2024/2024-0846-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression